The earnings call reflects a period of transition for Vivos Therapeutics, with significant investments and strategic changes aimed at long-term growth through the SCN acquisition and deployment of SO teams. While the company has secured financing and reports early success with SCN, current financial performance has been negatively impacted by decreased revenue and increased operating losses.

Company Guidance

In the second quarter of 2025, Vivos Therapeutics, Inc. experienced a 6% revenue decline to $3.8 million compared to the same period in 2024, partially due to the strategic pivot from their VIP enrollment model, which saw a $1.7 million drop. However, the company reported a $500,000 increase in sleep testing service revenue post-acquisition of the Sleep Center of Nevada (SCN) on June 10, 2025, which also contributed an additional $500,000 uplift in sponsorship, seminar, and other service revenue. The acquisition led to a significant rise in costs, including $1.8 million in expenses related to SCN integration and operating expenses, pushing the operating loss to $4.9 million for the quarter. Despite these challenges, the company secured $11.5 million in net cash from financing activities, including equity financing from Seneca Partners, and anticipates future revenue growth through the deployment of Sleep Optimization Teams (SO teams) and additional acquisitions. Vivos Therapeutics remains optimistic about the strategic transition and expects cash flow positivity in the fourth quarter of 2025 as they continue expanding their operations and facilities.

SCN Acquisition and Integration

Vivos Therapeutics completed the acquisition of the Sleep Center of Nevada (SCN) on June 10, 2025. The acquisition contributed $500,000 in sleep testing service revenue within just 20 days of closing. The company is encouraged by the cooperation and buy-in from the SCN medical team.

Deployment of Sleep Optimization Teams

Vivos has deployed 1.5 new sleep optimization (SO) teams and plans to expand to 4.5 teams across two SCN locations by the end of 2025. Each SO team is expected to generate over $500,000 in monthly net collections with contribution margins above 50%.

Significant Financing Secured

The company secured $11.5 million in net cash from financing activities, supported by an affiliate of Seneca Partners, to fund the SCN acquisition and support future growth.

Vivos Therapeutics (VVOS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VVOS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.48 / -	-0.4	―	―	―
Aug 19, 2025	2025 (Q2)	-0.38 / -0.55	-0.6	8.33% (+0.05)	―
May 15, 2025	2025 (Q1)	- / -0.45	-1.63	72.39% (+1.18)	―
Mar 31, 2025	2024 (Q4)	-0.40 / -0.45	-1.63	72.39% (+1.18)	―
Nov 14, 2024	2024 (Q3)	-0.66 / -0.40	-1.75	77.14% (+1.35)	―
Aug 14, 2024	2024 (Q2)	-1.05 / -0.60	-4.5	86.67% (+3.90)	―
May 14, 2024	2024 (Q1)	-1.18 / -1.63	-1.75	6.86% (+0.12)	―
Mar 28, 2024	2023 (Q4)	-1.91 / -3.14	-4.75	33.89% (+1.61)	―
Nov 14, 2023	2023 (Q3)	-3.00 / -1.75	-6.5	73.08% (+4.75)	―
Aug 16, 2023	2023 (Q2)	-3.63 / -4.50	-8.25	45.45% (+3.75)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VVOS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 19, 2025	$4.27	$4.13	-3.28%
May 15, 2025	$3.06	$2.54	-16.99%
Mar 31, 2025	$2.85	$2.63	-7.72%
Nov 14, 2024	$3.12	$2.84	-8.97%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vivos Therapeutics (VVOS) report earnings?

Vivos Therapeutics (VVOS) is schdueled to report earning on Nov 12, 2025, After Close (Confirmed).

What is Vivos Therapeutics (VVOS) earnings time?

Vivos Therapeutics (VVOS) earnings time is at Nov 12, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VVOS EPS forecast?

VVOS EPS forecast for the fiscal quarter 2025 (Q3) is -0.48.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing